These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38669053)

  • 1. First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study.
    Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau HT; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B
    Cancer Res Commun; 2024 Jun; 4(6):1609-1619. PubMed ID: 38669053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Podcast on Practical Considerations in Patients with Advanced Urothelial Cancer Receiving First-Line Cisplatin- or Carboplatin-Based Chemotherapy Followed by Avelumab Maintenance in a Changing Therapeutic Landscape.
    Gong J; Reimers MA
    Adv Ther; 2024 Sep; 41(9):3441-3451. PubMed ID: 39023740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
    Rizvi NA; Hellmann MD; Brahmer JR; Juergens RA; Borghaei H; Gettinger S; Chow LQ; Gerber DE; Laurie SA; Goldman JW; Shepherd FA; Chen AC; Shen Y; Nathan FE; Harbison CT; Antonia S
    J Clin Oncol; 2016 Sep; 34(25):2969-79. PubMed ID: 27354481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer.
    Yamamoto N; Satouchi M; Doi T; Fujiwara Y; Yanagitani N; Kawa Y; Yoh K; Leopold L; Munteanu M; Sawada T; Han S; Noguchi K; Nishio M
    Invest New Drugs; 2024 Jun; 42(3):261-271. PubMed ID: 38530565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study.
    Rodriguez-Vida A; Valderrama BP; Castellano D; Pinto A; Mellado B; Puente J; Climent MA; Domenech M; Vazquez F; Perez-Gracia JL; Bonfill T; Morales-Barrera R; Gonzalez-Billalabeitia E; Garcia-Del-Muro X; Maroto P; Navarro-Gorro N; Juanpere N; Juan O; Bellmunt J
    ESMO Open; 2024 Sep; 9(9):103690. PubMed ID: 39214051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
    Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
    Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
    Powles T; Park SH; Voog E; Caserta C; Valderrama BP; Gurney H; Kalofonos H; Radulović S; Demey W; Ullén A; Loriot Y; Sridhar SS; Tsuchiya N; Kopyltsov E; Sternberg CN; Bellmunt J; Aragon-Ching JB; Petrylak DP; Laliberte R; Wang J; Huang B; Davis C; Fowst C; Costa N; Blake-Haskins JA; di Pietro A; Grivas P
    N Engl J Med; 2020 Sep; 383(13):1218-1230. PubMed ID: 32945632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan.
    Kikuchi E; Hayakawa N; Nakayama M; Uno M; Nakatsu H; Kitagawa C; Miyake H; Yamada T; Fujita K; Shimoyama H; Nishihara K; Kobayashi M; Nakamura M; Fujimoto K; Sano T; Nishiyama N; Ito T; Kajita M; Kobayashi T; Kitamura H
    Int J Urol; 2024 Aug; 31(8):859-867. PubMed ID: 38722221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve.
    Gross-Goupil M; Domblides C; Lefort F; Ravaud A
    Bull Cancer; 2020 Jun; 107(5S):eS1-eS7. PubMed ID: 32620210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis.
    Apolo AB; Ellerton JA; Infante JR; Agrawal M; Gordon MS; Aljumaily R; Gourdin T; Dirix L; Lee KW; Taylor MH; Schöffski P; Wang D; Ravaud A; Manitz J; Pennock G; Ruisi M; Gulley JL; Patel MR
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
    Greystoke A; Steele N; Arkenau HT; Blackhall F; Md Haris N; Lindsay CR; Califano R; Voskoboynik M; Summers Y; So K; Ghiorghiu D; Dymond AW; Hossack S; Plummer R; Dean E
    Br J Cancer; 2017 Sep; 117(7):938-946. PubMed ID: 28950288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.
    Tfayli A; Al Assaad M; Fakhri G; Akel R; Atwi H; Ghanem H; El Karak F; Farhat F; Al Rabi K; Sfeir P; Youssef P; Mansour Z; Assi H; Haidar M; Abi Ghanem A; Khalifeh I; Boulos F; Mahfouz R; Youssef B; Zeidan Y; Bejjany R; Khuri F
    Cancer Med; 2020 Nov; 9(22):8406-8411. PubMed ID: 32991781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma.
    Hoffman-Censits J; Grivas P; Powles T; Hawley J; Tyroller K; Seeberger S; Guenther S; Jacob N; Mehr KT; Hahn NM
    Future Oncol; 2024 Feb; 20(4):179-190. PubMed ID: 37671748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
    Kanda S; Goto K; Shiraishi H; Kubo E; Tanaka A; Utsumi H; Sunami K; Kitazono S; Mizugaki H; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Hozumi H; Tamura T
    Ann Oncol; 2016 Dec; 27(12):2242-2250. PubMed ID: 27765756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer].
    Huang Y; Liu Y; Zhou J; Xu N; Li B; Wu G; Fang J; Li K; Liu X; Liu W; Lu Y; Wang M; Liu W; Liang H; Zhang Y; Huang C; Wang S; Wang Y; Yu S; Chang J; Wang Z; Hu Z; Zhang L
    Zhongguo Fei Ai Za Zhi; 2012 Oct; 15(10):576-82. PubMed ID: 23075681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
    Galsky MD; Arija JÁA; Bamias A; Davis ID; De Santis M; Kikuchi E; Garcia-Del-Muro X; De Giorgi U; Mencinger M; Izumi K; Panni S; Gumus M; Özgüroğlu M; Kalebasty AR; Park SH; Alekseev B; Schutz FA; Li JR; Ye D; Vogelzang NJ; Bernhard S; Tayama D; Mariathasan S; Mecke A; Thåström A; Grande E;
    Lancet; 2020 May; 395(10236):1547-1557. PubMed ID: 32416780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.
    Lee JL; Desai C; Park SH; Tsuchiya N; Su PJ; Chan TTW; Gurney H; Gao S; Wang J; Sandner R; di Pietro A; Eto M
    Urol Oncol; 2023 May; 41(5):256.e17-256.e25. PubMed ID: 37019764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer.
    Kanda S; Ohe Y; Goto Y; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Yamamoto T; Tamura T
    Cancer Sci; 2020 Jun; 111(6):1933-1942. PubMed ID: 32277531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
    Mazzanti P; Massacesi C; Rocchi MB; Mattioli R; Lippe P; Trivisonne R; Buzzi F; De Signoribus G; Tuveri G; Rossi G; Di Lullo L; Sturba F; Morale D; Catanzani S; Pilone A; Bonsignori M; Battelli T
    Lung Cancer; 2003 Jul; 41(1):81-9. PubMed ID: 12826316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.